Patients in the EU with rare disease thymidine kinase 2 deficiency (TK2d) have their first approved therapy, UCB's Kygevvi, after the European Commission cleared the drug "under exceptional ...

Combination therapy with multiple biologics may be on the horizon for patients with psoriatic arthritis, according to a ...

Over the past decade, neurodegenerative research and development has responsibly answered a foundational question: can we ...